- Home
- SFL vs ARDX Comparison
SFL vs ARDX Comparison
Compare SFL & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFL
- ARDX
- Stock Information
- Founded
- SFL 2003
- ARDX 2007
- Country
- SFL Bermuda
- ARDX United States
- Employees
- SFL N/A
- ARDX N/A
- Industry
- SFL Marine Transportation
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- SFL Consumer Discretionary
- ARDX Health Care
- Exchange
- SFL Nasdaq
- ARDX Nasdaq
- Market Cap
- SFL 1.7B
- ARDX 1.4B
- IPO Year
- SFL N/A
- ARDX 2014
- Fundamental
- Price
- SFL $11.00
- ARDX $5.31
- Analyst Decision
- SFL Strong Buy
- ARDX Buy
- Analyst Count
- SFL 1
- ARDX 7
- Target Price
- SFL $16.00
- ARDX $11.75
- AVG Volume (30 Days)
- SFL 952.7K
- ARDX 5.9M
- Earning Date
- SFL 11-06-2024
- ARDX 10-31-2024
- Dividend Yield
- SFL 9.83%
- ARDX N/A
- EPS Growth
- SFL 39.68
- ARDX N/A
- EPS
- SFL 1.10
- ARDX N/A
- Revenue
- SFL $876,068,000.00
- ARDX $251,849,000.00
- Revenue This Year
- SFL $20.56
- ARDX $167.24
- Revenue Next Year
- SFL N/A
- ARDX $18.93
- P/E Ratio
- SFL $10.00
- ARDX N/A
- Revenue Growth
- SFL 19.50
- ARDX 87.57
- 52 Week Low
- SFL $10.01
- ARDX $4.06
- 52 Week High
- SFL $14.62
- ARDX $10.13
- Technical
- Relative Strength Index (RSI)
- SFL 57.64
- ARDX 48.16
- Support Level
- SFL $10.01
- ARDX $4.63
- Resistance Level
- SFL $11.18
- ARDX $6.53
- Average True Range (ATR)
- SFL 0.29
- ARDX 0.44
- MACD
- SFL 0.09
- ARDX 0.01
- Stochastic Oscillator
- SFL 84.19
- ARDX 44.27
About SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship owning and chartering company. The company is engaged primarily in the ownership and operation of vessels and offshore related assets and is also involved in the charter, purchase, and sale of assets. Its oil tankers, chemical tankers, and oil product tankers are all double-hull vessels.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.